文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

选择性缓激肽 B1 受体拮抗剂 R-954 阻断与糖尿病发展相关的早期和晚期视网膜生化改变。

Blockade of early and late retinal biochemical alterations associated with diabetes development by the selective bradykinin B1 receptor antagonist R-954.

机构信息

Departamento de Biologia, Universidad Argentina John F Kennedy, Buenos Aires, Argentina.

出版信息

Peptides. 2012 Apr;34(2):349-52. doi: 10.1016/j.peptides.2012.02.008. Epub 2012 Feb 19.


DOI:10.1016/j.peptides.2012.02.008
PMID:22369720
Abstract

The chronic hyperglycemia measured alongside diabetes development is associated with significant long-term damage and failure of various organs. In the present study it was shown that hyperglycemia induced early and long term increases in nitric oxide (NO) levels, kallikrein activity and vascular capillary permeability measured as plasma extravasation, and decreases of Na/K ATPase activity in diabetic rat retina 4 and 12 weeks after streptozotocin (STZ) injection. Treatment of the animals for 5 consecutive days with a novel selective bradykinin B(1) receptor (BKB(1)-R) antagonist R-954 (2mg/kg s.c) at the end of the 4 and 12 week periods highly reduced NO, kallikrein and capillary permeability and increased Na/K ATPase activity in the retina. These results suggest that the BKB(1)-R receptor subtype is over-expressed during the streptozotocin-induced development of diabetes in rat retina as evidenced by the inhibitory effects of the BKB(1)-R antagonist R-954 on NO, kallikrein and vascular permeability increases as well as Na/K ATPase decreases. The beneficial role of the BKB(1)-R antagonist R-954 for the treatment of the diabetic retinopathy is also suggested.

摘要

与糖尿病发展同时测量的慢性高血糖与各种器官的显著长期损伤和衰竭有关。在本研究中表明,高血糖诱导了糖尿病大鼠视网膜中一氧化氮(NO)水平、激肽释放酶活性和血管毛细血管通透性(作为血浆渗出测量)的早期和长期增加,以及在链脲佐菌素(STZ)注射后 4 和 12 周时 Na/K ATPase 活性的降低。在第 4 和 12 周结束时,连续 5 天每天用新型选择性缓激肽 B(1)受体(BKB(1)-R)拮抗剂 R-954(2mg/kg sc)对动物进行治疗,可高度降低视网膜中的 NO、激肽释放酶和毛细血管通透性,并增加 Na/K ATPase 活性。这些结果表明,在大鼠视网膜的链脲佐菌素诱导的糖尿病发展过程中,BKB(1)-R 受体亚型过度表达,这可通过 BKB(1)-R 拮抗剂 R-954 对 NO、激肽释放酶和血管通透性增加以及 Na/K ATPase 降低的抑制作用得到证明。BKB(1)-R 拮抗剂 R-954 对糖尿病性视网膜病变的治疗作用也得到了提示。

相似文献

[1]
Blockade of early and late retinal biochemical alterations associated with diabetes development by the selective bradykinin B1 receptor antagonist R-954.

Peptides. 2012-2-19

[2]
Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a selective bradykinin B1 receptor antagonist.

Regul Pept. 2005-1-15

[3]
Effects of a selective bradykinin B1 receptor antagonist on increased plasma extravasation in streptozotocin-induced diabetic rats: distinct vasculopathic profile of major key organs.

Eur J Pharmacol. 2005-5-2

[4]
Bradykinin B₁ antagonism inhibits oxidative stress and restores Na+K+ ATPase activity in diabetic rat peripheral nervous system.

Peptides. 2013-3-23

[5]
Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy.

Curr Opin Investig Drugs. 2010-5

[6]
Expression, distribution and function of kinin B receptor in the rat diabetic retina.

Br J Pharmacol. 2018-2-13

[7]
Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats.

Invest Ophthalmol Vis Sci. 1997-3

[8]
Captopril ameliorates the decreased Na+,K(+)-ATPase activity in the retina of streptozotocin-induced diabetic rats.

Invest Ophthalmol Vis Sci. 1996-7

[9]
Chronic taurine supplementation ameliorates oxidative stress and Na+ K+ ATPase impairment in the retina of diabetic rats.

Amino Acids. 2002

[10]
Modulation of retinal blood flow by kinin B₁ receptor in Streptozotocin-diabetic rats.

Exp Eye Res. 2011-3-21

引用本文的文献

[1]
Pharmacotherapy and Nutritional Supplements for Neovascular Eye Diseases.

Medicina (Kaunas). 2023-7-20

[2]
Targeting Plasma Kallikrein With a Novel Bicyclic Peptide Inhibitor (THR-149) Reduces Retinal Thickening in a Diabetic Rat Model.

Invest Ophthalmol Vis Sci. 2021-10-4

[3]
Recent Advancements in the Medical Treatment of Diabetic Retinal Disease.

Int J Mol Sci. 2021-8-31

[4]
Kinins and Their Receptors as Potential Therapeutic Targets in Retinal Pathologies.

Cells. 2021-7-28

[5]
Roles of Drug Transporters in Blood-Retinal Barrier.

Adv Exp Med Biol. 2019

[6]
Neuroprotective Peptides in Retinal Disease.

J Clin Med. 2019-8-1

[7]
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-A/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.

Diabetologia. 2019-3-5

[8]
Expression, distribution and function of kinin B receptor in the rat diabetic retina.

Br J Pharmacol. 2018-2-13

[9]
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

J Clin Endocrinol Metab. 2017-12-1

[10]
Diabetic retinopathy: Breaking the barrier.

Pathophysiology. 2017-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索